Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE) (PINNACLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03514719
Recruitment Status : Recruiting
First Posted : May 2, 2018
Last Update Posted : April 4, 2019
Sponsor:
Collaborator:
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):
Radboud University

Brief Summary:

In this feasibility study, a zirconium-89 (89Zr)-avelumab positron emission tomography (PET) scan will be performed in 37 patients prior to treatment with avelumab to:

  1. assess the tumor and systemic tissue uptake 89Zr-avelumab
  2. assess the potential to predict avelumab treatment response

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Diagnostic Test: 89Zr-avelumab PET Drug: Avelumab Phase 1

Detailed Description:

The programmed death 1 (PD1)/ programmed death ligand 1 (PD-L1) pathway plays an important role in regulating the T-cell anti tumor response. Blocking this interaction with the anti PD-L1 monoclonal antibody avelumab is effective in patients with non-small cell lung cancer (NSCLC) resulting in durable disease control rates. Currently, PD-L1 expression as determined by immune histochemistry (IHC) is the best available biomarker for treatment response, but standardized scoring criteria are lacking and the risk for sampling errors exists. Molecular imaging using 89Zr-labeled antibodies may overcome these limitations, enabling the visualization of PD-L1 expression in primary and metastatic tumor lesions and providing information on the in vivo accessibility of the PD-L1 target following intravenous administration.

This study enables PD-L1 PET-imaging with 89Zr-avelumab in patients with:

  • early stage NSCLC (stage Ia (≥T1b) -IIIa) followed by 2 cycles of neo-adjuvant avelumab treatment and surgical resection of the tumor.
  • advanced stage NSCLC (Stage IIIb-IV) followed by avelumab treatment until disease progression or intolerable toxicity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 37 participants
Intervention Model: Single Group Assignment
Intervention Model Description:

Patients with early stage disease (stage Ia(≥T1b)-IIIa) undergo pre-treatment PET-imaging and 2 cycles of neo-adjuvant avelumab treatment. Followed by surgical resection of the tumor.

Patients with stage IIIb-IV NSCLC will undergo pre-treatment PET-imaging in only part 1 of the study, and receive avelumab treatment 10mg/kg q2w until disease progression or treatment toxicity

Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)
Actual Study Start Date : October 1, 2018
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : November 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Avelumab

Arm Intervention/treatment
Experimental: 89Zr-avelumab PET
89Zr-avelumab injection followed by 89Zr-avelumab PET
Diagnostic Test: 89Zr-avelumab PET
89Zr-avelumab injection followed by 89Zr-Avelumab PET scan
Other Name: ImmunoPET

Drug: Avelumab

Early stage disease (stage Ia (≥T1b tumor)-IIIa: neo-adjuvant avelumab treatment (10mg/kg iv q2w) for a maximum duration of 2 cycles after PET-imaging, followed by surgical resection of the tumor with curative intent

Stage IIIb-IV disease: systemic treatment with avelumab 10mg/kg iv q2w after PET-imaging





Primary Outcome Measures :
  1. Tumor uptake of 89Zr-Avelumab [ Time Frame: 1 year ]
    Standardized uptake values (SUV) of 89Zr-Avelumab uptake in tumor lesions will be measured


Secondary Outcome Measures :
  1. Correlation 89Zr-Avelumab uptake in tumor lesions and PD-L1 expression as determined by immunohistochemistry [ Time Frame: 1-2 year ]
  2. Correlation between 89Zr-Avelumab uptake in tumor lesions and response to (neo)-adjuvant avelumab treatment [ Time Frame: 1-2 years ]
    To assess the potential of PD-L1 PET/CT to image PD-L1 expression in tumor lesions, and predict response to (neo)-adjuvant avelumab treatment in patients with NSCLC

  3. The number of treatment delays in surgical resections [ Time Frame: 1-2 years ]
    In resectable early stage disease (stage Ia (≥T1b) - IIIa)

  4. Asses post-operative complications [ Time Frame: 1-2 years ]
    In resectable early stage disease (stage Ia (≥T1b) - IIIa)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female subjects aged ≥ 18 years, and >50 years in patients with resectable stage Ia (≥T1b tumor) - IIIa NSCLC)
  2. Histological or cytologic proven stage IIIb/IV NSCLC or resectable stage Ia (≥T1b tumor) - IIIa NSCLC, where no pathological evaluation of mediastinal lymph nodes by mediastinoscopy is indicated according to the multidisciplinary tumor board
  3. ECOG performance score (0-1)
  4. At least one lesion with a tumour size ≥ 1 cm
  5. Haematologic function: absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, and haemoglobin ≥ 9 g/dL (may have been transfused)
  6. Hepatic function: total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range and AST and ALT levels ≤ 2.5 × ULN for all subjects or AST and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the liver).
  7. Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method)
  8. Highly effective contraception for both male and female subjects throughout the study and for at least after avelumab treatment administration intrinsic factor the risk of conception exists
  9. Fit for surgery (for patients with resectable stage Ia-IIIa disease), as assessed by treating thoracic surgeon / anesthesiologists based on sufficient cardiopulmonary status and absence of major contra-indications for surgery according to local guidelines

Exclusion Criteria:

  1. Immunosuppressants: "Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (eg, intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)."
  2. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent: Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
  3. Prior organ transplantation, including allogeneic stem cell transplantation
  4. Infections: active infection requiring systemic therapy
  5. HIV/AIDS: known history for testing positive to an HIV test or known acquired immunodeficiency syndrome (AIDS)
  6. Hepatitis: hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or confirmatory HCV RNA if anti-HCV antibody screening test positive)
  7. Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
  8. Hypersensitivity to study drug: "Known prior severe hypersensitivity reactions to investigational product or any component in its formulations, including known severe hypersensitivity reactions to antibodies (Grade ≥ 3 NCI CTCAE v 4.03)
  9. Cardiovascular disease: "Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication."8. Persisting toxicity related to prior therapy of Grade >1 NCI-CTCAE v 4.03; however, alopecia and sensory neuropathy Grade ≤ 2 is acceptable
  10. Other persisting toxicities: Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 > 1); however, alopecia, sensory neuropathy Grade

    ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.

  11. Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03514719


Contacts
Layout table for location contacts
Contact: Sarah Verhoeff, MD +31243618800 sarah.verhoeff@radboudumc.nl

Locations
Layout table for location information
Netherlands
Radboud University Recruiting
Nijmegen, Netherlands
Contact: Carla van Herpen, Professor       carla.vanHerpen@radboudumc.nl   
Contact: Sarah Verhoeff, MD       sarah.verhoeff@radboudumc.nl   
Principal Investigator: C.M.L. van Herpen, Prof.dr.         
Sub-Investigator: M. van den Heuvel, Prof.dr.         
Sub-Investigator: S.R. Verhoeff, MD         
Sub-Investigator: E.H. Aarntzen, MD, PhD         
Sub-Investigator: S Heskamp, MD, PhD         
Sponsors and Collaborators
Radboud University
Merck KGaA, Darmstadt, Germany
Investigators
Layout table for investigator information
Principal Investigator: C.M.L. van Herpen, Prof.dr. Radboud University

Layout table for additonal information
Responsible Party: Radboud University
ClinicalTrials.gov Identifier: NCT03514719     History of Changes
Other Study ID Numbers: MS100070_0167
First Posted: May 2, 2018    Key Record Dates
Last Update Posted: April 4, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Radboud University:
89Zr-avelumab PET
avelumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs